PrimeRFP SCOUT · Federal Contract Recompete Brief

36C25226N0204Revlimid pomalyst camzyos specialty — Bristol-Myers Squibb Company

Bristol-Myers Squibb Company holds $17.3M across 91 federal awards, concentrated at Department of Veterans Affairs (VA). This PIID sits alongside 5 related awards under parent 36F79724D0101. The prior award was single-bid — competitive dynamics may favor a challenge. Recompete timing centers on the Jan 12, 2027 PoP end — agencies typically plan 12–18 months ahead.

252-Network Contract Office 12 (36C252)
Awarding office
Bristol-Myers Squibb Company
Recipient
Jan 12, 2027
PoP end
$911K
Obligated
$911K
Potential
325412
NAICS
6505
PSC
1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Bristol-Myers Squibb Company — $90

Contract facts

Federal
Contract number36C25226N0204
Also listed as36C252-26-N-0204
Also listed as36F79724D0101-36C25226N0204
Agency252-Network Contract Office 12 (36C252)
Awarding office252-Network Contract Office 12 (36C252)
Awarding agencyDepartment of Veterans Affairs (VA)
Funding agencyDepartment of Veterans Affairs (VA)
IncumbentBristol-Myers Squibb Company
CAGE4K2D9
UEIUFGKB2B71N12
NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505
Parent IDIQ / IDV36F79724D0101
Place of performanceLAWRENCEVILLE NJ
Pricing typeFirm Fixed Price
Extent competedFull And Open Competition
PoP startJan 13, 2026
PoP end (current)Jan 12, 2027
Obligated$911K
Current value$911K
Potential value$911K

REVLIMID, POMALYST, CAMZYOS SPECIALTY PHARMACEUTICALS is a federal award for 252-Network Contract Office 12 (36C252) held by Bristol-Myers Squibb Company. Estimated value $911K ($911K obligated). Current period of performance ends Jan 12, 2027. Last award drew 1 bidder. Place of performance: LAWRENCEVILLE NJ.

REVLIMID, POMALYST, CAMZYOS SPECIALTY PHARMACEUTICALS

Recompete timing

Public
Expiring in 144 days

Current PoP ends Jan 12, 2027 (144 days remaining). Agencies typically plan 12–18 months ahead — at 4.7 months out, that window is already open. The buying decision is likely already in motion.

Incumbent footprint

Public record

Bristol-Myers Squibb Company$17.3M obligated across 91 awards (firm-wide, all agencies) · lead buyer Department of Veterans Affairs (VA).

% of firm-wide obligated ($17.3M) · all agencies
Department of Veterans Affairs (VA)$17.3M · 100%Department of Justice (DOJ)$23K · 0%
Open full company profile

Related awards

Same parent · incumbent
36C24926F0137
BREYANZI CAR T-TRANSPLANT
$364K
Aug 31, 2026
36C24526N0790
POMALYST 2 MG, 3 MG,4 MG
$199K
Aug 31, 2026
36C24926N0526
BREYANZI CAT-T TRANSPLANT
$364K
Sep 1, 2026
36C24926F0096
ABECMA FOR CAR-T
$379K
Sep 12, 2026
36C24926N0589
BREYANZI CAR T
$364K
Sep 17, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

More in SCOUT
Size up the competition →Research the incumbent →

Frequently asked questions

What is contract 36C25226N0204?

36C25226N0204 (Revlimid pomalyst camzyos specialty) is a 252-Network Contract Office 12 (36C252) award with a potential value of $911K, currently held by Bristol-Myers Squibb Company. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C252-26-N-0204?

36C252-26-N-0204 is the dashed form of PIID 36C25226N0204 (Revlimid pomalyst camzyos specialty), held by Bristol-Myers Squibb Company. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C25226N0204?

252-Network Contract Office 12 (36C252) awarded 36C25226N0204 to Bristol-Myers Squibb Company (potential $911K).

Who is the incumbent on 36C25226N0204?

Bristol-Myers Squibb Company is the incumbent with $17.3M across 91 related awards in SCOUT’s public footprint. The current period of performance ends Jan 12, 2027.

When does Bristol-Myers Squibb Company’s 36C25226N0204 come up for recompete?

SCOUT tracks a period-of-performance end of Jan 12, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/36C25226N0204